You are here



Reference is made to NorDiag ASA's ("NorDiag" or the "Company") stock exchange announcement on 8 March 2012 regarding the strategic process with the aim to either offer the shareholders an exit opportunity, or to secure the Company's long-term capital need by attracting strategic investors.
The Board of Directors of the Company has decided to call for an Extraordinary General Meeting to be held 16 April 2012. Among the proposals are approval of the issuance of shares and warrants, and an authority for the Board of Directors to issue shares, as well as approval of a potential asset sale of the Company's business.
The background for the proposals is further set forth in the attached notice.
For further information, please contact:
CEO Mårten Wigstøl             Phone: +47 911 65775
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
Notice of EGM

Read the notice in Norwegian here.